These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

184 related articles for article (PubMed ID: 24370448)

  • 1. Fatty acids and TxA(2) generation, in the absence of platelet-COX-1 activity.
    DeFilippis AP; Rai SN; Cambon A; Miles RJ; Jaffe AS; Moser AB; Jones RO; Bolli R; Schulman SP
    Nutr Metab Cardiovasc Dis; 2014 Apr; 24(4):428-33. PubMed ID: 24370448
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Thromboxane A(2) generation, in the absence of platelet COX-1 activity, in patients with and without atherothrombotic myocardial infarction.
    DeFilippis AP; Oloyede OS; Andrikopoulou E; Saenger AK; Palachuvattil JM; Fasoro YA; Guallar E; Blumenthal RS; Kickler TS; Jaffe AS; Gerstenblith G; Schulman SP; Rade JJ
    Circ J; 2013; 77(11):2786-92. PubMed ID: 23985963
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Residual platelet thromboxane A2 and prothrombotic effects of erythrocytes are important determinants of aspirin resistance in patients with vascular disease.
    Santos MT; Valles J; Lago A; Tembl J; Sánchez E; Moscardo A; Cosin J
    J Thromb Haemost; 2008 Apr; 6(4):615-21. PubMed ID: 18221358
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Aspirin resistance detected with aggregometry cannot be explained by cyclooxygenase activity: involvement of other signaling pathway(s) in cardiovascular events of aspirin-treated patients.
    Ohmori T; Yatomi Y; Nonaka T; Kobayashi Y; Madoiwa S; Mimuro J; Ozaki Y; Sakata Y
    J Thromb Haemost; 2006 Jun; 4(6):1271-8. PubMed ID: 16706971
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Suboptimal inhibition of platelet cyclooxygenase-1 by aspirin in metabolic syndrome.
    Smith JP; Haddad EV; Taylor MB; Oram D; Blakemore D; Chen Q; Boutaud O; Oates JA
    Hypertension; 2012 Mar; 59(3):719-25. PubMed ID: 22311905
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Residual cyclooxygenase-1 activity and epinephrine reduce the antiplatelet effect of aspirin in patients with acute myocardial infarction.
    Moscardó A; Santos MT; Fuset MP; Ruano M; Vallés J
    Thromb Haemost; 2011 Apr; 105(4):663-9. PubMed ID: 21301784
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Heritability of platelet responsiveness to aspirin in activation pathways directly and indirectly related to cyclooxygenase-1.
    Faraday N; Yanek LR; Mathias R; Herrera-Galeano JE; Vaidya D; Moy TF; Fallin MD; Wilson AF; Bray PF; Becker LC; Becker DM
    Circulation; 2007 May; 115(19):2490-6. PubMed ID: 17470694
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Human pharmacology of naproxen sodium.
    Capone ML; Tacconelli S; Sciulli MG; Anzellotti P; Di Francesco L; Merciaro G; Di Gregorio P; Patrignani P
    J Pharmacol Exp Ther; 2007 Aug; 322(2):453-60. PubMed ID: 17473175
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Heterogeneity in the suppression of platelet cyclooxygenase-1 activity by aspirin in coronary heart disease.
    Sciulli MG; Renda G; Capone ML; Tacconelli S; Ricciotti E; Manarini S; Evangelista V; Rebuzzi A; Patrignani P
    Clin Pharmacol Ther; 2006 Aug; 80(2):115-25. PubMed ID: 16890573
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cardiovascular events occur independently of high on-aspirin platelet reactivity and residual COX-1 activity in stable cardiovascular patients.
    Nagatsuka K; Miyata S; Kada A; Kawamura A; Nakagawara J; Furui E; Takiuchi S; Taomoto K; Kario K; Uchiyama S; Saito K; Nagao T; Kitagawa K; Hosomi N; Tanaka K; Kaikita K; Katayama Y; Abumiya T; Nakane H; Wada H; Hattori A; Kimura K; Isshiki T; Nishikawa M; Yamawaki T; Yonemoto N; Okada H; Ogawa H; Minematsu K; Miyata T
    Thromb Haemost; 2016 Aug; 116(2):356-68. PubMed ID: 27098431
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Partial inhibition of platelet thromboxane A2 synthesis by aspirin is associated with myonecrosis in patients with ST-segment elevation myocardial infarction.
    Valles J; Santos MT; Fuset MP; Moscardo A; Ruano M; Perez F; Piñon M; Breña S; Aznar J
    Am J Cardiol; 2007 Jan; 99(1):19-25. PubMed ID: 17196455
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effect of atorvastatin on platelet thromboxane A(2) synthesis in aspirin-treated patients with acute myocardial infarction.
    Santos MT; Fuset MP; Ruano M; Moscardó A; Valles J
    Am J Cardiol; 2009 Dec; 104(12):1618-23. PubMed ID: 19962464
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Residual platelet reactivity in low-dose aspirin-treated patients with class 1 obesity.
    Lee S; Eichelberger B; Kopp CW; Panzer S; Gremmel T
    Vascul Pharmacol; 2021 Feb; 136():106819. PubMed ID: 33207279
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Increased platelet sensitivity among individuals with aspirin resistance - platelet aggregation to submaximal concentration of arachidonic acid predicts response to antiplatelet therapy.
    Guthikonda S; Mangalpally K; Vaduganathan M; Patel R; Delao T; Bergeron AL; Dong JF; Lev EI; Kleiman NS
    Thromb Haemost; 2008 Jul; 100(1):83-9. PubMed ID: 18612542
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Heterogeneity in platelet cyclooxygenase inhibition by aspirin in coronary artery disease.
    Lordkipanidzé M; Pharand C; Schampaert E; Palisaitis DA; Diodati JG
    Int J Cardiol; 2011 Jul; 150(1):39-44. PubMed ID: 20207433
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The contribution of cyclooxygenase-1 and -2 to persistent thromboxane biosynthesis in aspirin-treated essential thrombocythemia: implications for antiplatelet therapy.
    Dragani A; Pascale S; Recchiuti A; Mattoscio D; Lattanzio S; Petrucci G; Mucci L; Ferrante E; Habib A; Ranelletti FO; Ciabattoni G; Davì G; Patrono C; Rocca B
    Blood; 2010 Feb; 115(5):1054-61. PubMed ID: 19887674
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Aspirin and the in vitro linear relationship between thromboxane A2-mediated platelet aggregation and platelet production of thromboxane A2.
    Armstrong PC; Truss NJ; Ali FY; Dhanji AA; Vojnovic I; Zain ZN; Bishop-Bailey D; Paul-Clark MJ; Tucker AT; Mitchell JA; Warner TD
    J Thromb Haemost; 2008 Nov; 6(11):1933-43. PubMed ID: 18752570
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Evaluation of dose-related effects of aspirin on platelet function: results from the Aspirin-Induced Platelet Effect (ASPECT) study.
    Gurbel PA; Bliden KP; DiChiara J; Newcomer J; Weng W; Neerchal NK; Gesheff T; Chaganti SK; Etherington A; Tantry US
    Circulation; 2007 Jun; 115(25):3156-64. PubMed ID: 17562955
    [TBL] [Abstract][Full Text] [Related]  

  • 19. COX-1 sensitivity and thromboxane A2 production in type 1 and type 2 diabetic patients under chronic aspirin treatment.
    Pulcinelli FM; Biasucci LM; Riondino S; Giubilato S; Leo A; Di Renzo L; Trifirò E; Mattiello T; Pitocco D; Liuzzo G; Ghirlanda G; Crea F
    Eur Heart J; 2009 May; 30(10):1279-86. PubMed ID: 19346231
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A comparison of VerifyNowR with PlateletMappingR--detected aspirin resistance and correlation with urinary thromboxane.
    Carroll RC; Craft RM; Snider CC; Aligeti VR; Wortham DC
    Anesth Analg; 2013 Feb; 116(2):282-6. PubMed ID: 23302970
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.